Fabrizi Fabrizio, Bunnapradist Suphamai, Martin Paul
Division of Liver Diseases, Mount Sinai Medical Center and School of Medicine, One Gustave L. Levy Place, 1190 Fifth Ave., New York, NY 10029, USA.
Clin Liver Dis. 2005 Aug;9(3):487-503, viii. doi: 10.1016/j.cld.2005.05.006.
Hepatitis C virus (HCV) is common in certain solid organ transplant recipients, most notably in those undergoing liver or kidney transplantation. Infection typically antedates transplantation but may have been acquired at the time of transplantation via infected blood products or organs. A more rapid and aggressive course of HCV-related infection and liver disease is the major concern in organ transplant recipients compared with immunocompetent patients. HCV-related liver disease is an important cause of morbidity and mortality in patients with end-stage renal disease treated by dialysis or transplantation. The outcome of HCV infection in renal and liver transplant recipients has been extensively investigated, whereas literature on HCV-related liver disease among patients with orthotopic heart transplantation is scanty. This article reviews the literature concerning the treatment of HCV-related liver disease in renal and orthotopic heart transplantation.
丙型肝炎病毒（HCV）在某些实体器官移植受者中很常见，尤其是在接受肝移植或肾移植的患者中。感染通常发生在移植之前，但也可能在移植时通过受感染的血液制品或器官获得。与免疫功能正常的患者相比，器官移植受者中与HCV相关的感染和肝病病程更快且更具侵袭性，这是主要关注点。HCV相关肝病是接受透析或移植治疗的终末期肾病患者发病和死亡的重要原因。肾移植和肝移植受者中HCV感染的结局已得到广泛研究，而关于原位心脏移植患者中HCV相关肝病的文献却很少。本文综述了有关肾移植和原位心脏移植中HCV相关肝病治疗的文献。
